Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.64 |
| ▸ | PLK3 | Q9H4B4 | 15/20 | 0.64 |
| ▸ | PLK2 | Q9NYY3 | 14/20 | 0.64 |
| ▸ | BRD4 | O60885 | 5/20 | 0.60 |
| ▸ | TAF1 | P21675 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 2/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | NEK4 | P51957 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.53 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.53 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.53 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.53 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.53 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227769 | 0.90 | PLK1 (0.62) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL376326 | 0.90 | PLK1 (0.69) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL13227773 | 0.89 | PLK1 (0.61) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL375946 | 0.89 | PLK1 (0.61) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL376760 | 0.88 | PLK1 (0.60) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL376130 | 0.87 | PLK1 (0.68) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL375836 | 0.86 | PLK1 (0.56) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL13227781 | 0.83 | PLK1 (0.60) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL13261138 | 0.82 | PLK1 (0.65) | PLK1PLK3PLK2BRD4TAF1 | |
| SCHEMBL375905 | 0.82 | PLK1 (0.65) | PLK1PLK3PLK2BRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2079743-B1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD (GB) | 2012-01-25 | — | — | EP | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| EP-2079743-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | Chroma Therapeutics Limited (GB) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050096-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | PLK1 7/4885PLK3 3/4885PLK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.